近年来,随着ADC药物热度与市场规模的飙升,该领域药物开发已取得众多进展。目前,全球已上市的超20款ADC药物中,有靶向HER2、靶向Trop2,以及CD30、CD22、Nectin-4等,适应症包括白血病、骨髓瘤、淋巴癌、乳腺癌等。值得一提的是,聚焦国内市场,在技术突破和全球合作的推动下,2025年国内ADC领域的发展更是呈现出蓬勃的活力。不仅在产品和技术上取得显著突破,在出海和商业模式上也开始...
Source Link近年来,随着ADC药物热度与市场规模的飙升,该领域药物开发已取得众多进展。目前,全球已上市的超20款ADC药物中,有靶向HER2、靶向Trop2,以及CD30、CD22、Nectin-4等,适应症包括白血病、骨髓瘤、淋巴癌、乳腺癌等。值得一提的是,聚焦国内市场,在技术突破和全球合作的推动下,2025年国内ADC领域的发展更是呈现出蓬勃的活力。不仅在产品和技术上取得显著突破,在出海和商业模式上也开始...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.